Johnson & Johnson (NYSE:JNJ) Shares Purchased by Financial Architects Inc

Financial Architects Inc raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,822 shares of the company’s stock after acquiring an additional 260 shares during the quarter. Johnson & Johnson makes up about 1.2% of Financial Architects Inc’s holdings, making the stock its 19th largest holding. Financial Architects Inc’s holdings in Johnson & Johnson were worth $8,372,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. BlackRock Inc. boosted its position in Johnson & Johnson by 0.7% during the first quarter. BlackRock Inc. now owns 189,690,998 shares of the company’s stock worth $31,175,717,000 after acquiring an additional 1,379,656 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 1.8% during the 1st quarter. Geode Capital Management LLC now owns 40,825,241 shares of the company’s stock worth $6,691,186,000 after purchasing an additional 716,136 shares during the last quarter. Morgan Stanley grew its position in shares of Johnson & Johnson by 0.8% in the first quarter. Morgan Stanley now owns 24,305,948 shares of the company’s stock valued at $3,994,681,000 after purchasing an additional 194,920 shares in the last quarter. Nuveen Asset Management LLC lifted its position in Johnson & Johnson by 0.8% during the first quarter. Nuveen Asset Management LLC now owns 14,395,550 shares of the company’s stock worth $2,365,909,000 after buying an additional 119,687 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Johnson & Johnson by 1.8% during the first quarter. Swiss National Bank now owns 11,038,366 shares of the company’s stock worth $1,814,155,000 after buying an additional 192,000 shares during the last quarter. Institutional investors and hedge funds own 67.29% of the company’s stock.

Shares of JNJ traded up $0.40 during mid-day trading on Wednesday, hitting $165.20. 138,592 shares of the company’s stock were exchanged, compared to its average volume of 7,095,660. The stock’s 50-day moving average is $172.45 and its 200-day moving average is $167.19. The company has a market cap of $434.89 billion, a price-to-earnings ratio of 24.78, a P/E/G ratio of 2.23 and a beta of 0.71. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.13 and a current ratio of 1.39. Johnson & Johnson has a fifty-two week low of $133.65 and a fifty-two week high of $179.92.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.19. The company had revenue of $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The firm’s quarterly revenue was up 27.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.67 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.65 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were given a $1.06 dividend. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 52.80%.

JNJ has been the topic of several recent research reports. Morgan Stanley cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price target on the stock. in a research report on Tuesday, September 7th. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Finally, Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, June 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $190.38.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.